NAS
CRNX icon

Nykredit A/S’s Crinetics Pharmaceuticals CRNX Stock Holding History

Nykredit A/S’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.1K Buy
+2,487
New +$92.4K ﹤0.01% 1341

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nykredit A/S's CRNX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 2,487 shares worth $93.1K. The stake represents ﹤0.01% of the portfolio and ranks #1341 among its holdings.

185 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Nykredit A/S held 2,487 shares of Crinetics Pharmaceuticals worth $93.1K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1341 holding.
  • 185 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.